Our (European Renal Association AKI Working Group) comment on the DEFENDER RCT: academic.oup.com/ndt/advance-...
SGLT2 inhibitors in critically ill patients are safe but do not reduce mortality or length of stay in the hospital. RCTs testing SGLT2i for AKI prevention and treatment are needed.
academic.oup.com
DEFENDER Trial: Dapagliflozin for Critically Ill Patients with Acute Organ Dysfunction -Implications for clinicians
Jolanta Malyszko, the ERAKI Working group of the European Renal Association, Sophie De Seigneux, the ERAKI Working group of the European Renal Association,